Now that I own some Pfizer stock (due to the acquisition of Wyeth), I feel obligated to at least post on Pfizer’s earnings. (a href=”http://www.marketwatch.com/story/pfizer-reports-26-higher-profit-but-lower-sales-2009-10-20″marketwatch/a) br /br /-The world’s largest drug maker posted net income of $2.88 billion, or 43 cents a share, compared with $2.28 billion, or 34 cents a share, for the same quarter in 2008.br /br /-Excluding various items, Pfizer would have reported adjusted earnings of 51 cents a share, versus 62 cents. This year’s quarter was also impacted by a higher tax rate, due largely to its merger with Wyeth.br /br /-Revenue in the period fell 3% to $11.62 billion, from $11.97 billion.br /br /-Pfizer was expected to report lower year-over-year sales, with the loss of patent protection for such former blockbusters as Norvasc and Zyrtec weighing heavily on its top line.br /br /-Still, Pfizer’s sales results managed to top Wall Street’s expectations. According to a recent poll of analysts by FactSet Research, Pfizer was pegged at posting earnings of 48 cents a share on revenue of $11.44 billion.br /br /-On Oct. 15, Pfizer finally closed its $68 billion merger with Wyeth, which was scheduled to release its earnings Thursday. Pfizer halved its once-coveted dividend several months ago to help finance the takeover.br /br /-Pfizer also updated its 2009 financial forecast to reflect the acquisition. The drug maker now sees revenue of $49 billion to $50 billion, up from its previous forecast of $45 billion to $46 billion. Earnings are seen between $1.45 and $1.50 a share, up from $1.30 to $1.45. Adjusted earnings should come in between $2.00 and $2.05 a share, up from $1.90 to $2.00.br /br /I’m still making up my mind about this stock. As long as it continues to move higher, I’m not going to sell it. I don’t typically like companies that make massive acquisitions as I fell there is a lot of waste and its difficult to manage that many different operations and still grow. But they have a pretty strong sales pipeline now as Wyeth was a great company (that’s why I owned the stock). But Pfizer did have to cut their dividend to finance this deal, which is one of the reasons to like Pfizer in the first place. I haven’t had time to do a ton of research on this yet, so like I said, I’m still up in the air on Pfizer. br /br /Disclosure: Long PFEdiv class=”blogger-post-footer”img width=’1′ height=’1′ src=’https://blogger.googleusercontent.com/tracker/819581243324579563-3751828478083401374?l=briskycapital.blogspot.com’ alt=” //div

Last 5 posts by Michael E. Brisky

• More of the Same - November 11th, 2009
• Picked up Some RHIE - November 10th, 2009
• Loews Still Attractive - November 9th, 2009
• Tii Network Technologies Reports - November 9th, 2009
• Not So Fast, Bears... - November 9th, 2009